You are here

Article Text

Article menu
Download PDFPDF
Clinical science
Incidence of rhegmatogenous retinal detachment in France from 2010 to 2016: seasonal and geographical variations
  1. Inès Ben Ghezala1,
  2. Anne Sophie Mariet2,3,4,
  3. Eric Benzenine2,
  4. Pierre-Henry Gabrielle1,5,
  5. Florian Baudin1,
  6. Alain M Bron1,5,
  7. Catherine Quantin2,3,4,6,
  8. Catherine P Creuzot-Garcher1,5
  1. 1 Ophthalmology Department, Dijon University Hospital, Dijon, France
  2. 2 Biostatistics and Bioinformatics (DIM), Dijon University Hospital, Bourgogne Franche-Comté University, Dijon, France
  3. 3 INSERM, CIC 1432, Dijon, France
  4. 4 Clinical Epidemiology/Clinical Trials Unit, Clinical Investigation Center, Dijon University Hospital, Dijon, France
  5. 5 Eye and Nutrition Research Group, Centre des Sciences du Goût et de l'Alimentation, UMR1324, INRAE, 6265 CNRS, Dijon, France
  6. 6 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), INSERM, UVSQ, Institut Pasteur, Université Paris-Saclay, Paris, France
  1. Correspondence to Dr Inès Ben Ghezala, Ophthalmology Department, Dijon University Hospital, 21000 Dijon, France; ines.ben-ghezala{at}chu-dijon.fr

Abstract

Aims To investigate the annual and monthly hospital incidence rate of rhegmatogenous retinal detachments (RRDs) from 2010 to 2016 in France at the national and regional levels.

Methods In this nationwide database study, we identified hospital and clinic admissions of French residents for a first episode of RRD in France during 2010–2016 from the national administrative database. The annual and monthly hospital incidence rates of RRD per 100 000 population were calculated for the whole country and for each region.

Results The average annual national hospital incidence rate of RRD was 21.97±1.04 per 100 000 population. The annual national hospital incidence rate of RRD was the lowest in 2010 (20.91 per 100 000 population) after which it increased until 2015 (23.55 per 100 000 population). The average monthly national RRD hospital incidence rate was the highest in June (2.03±0.12 per 100 000 population) and the lowest in August (1.60±0.09). The average annual age-standardised and sex-standardised regional hospital incidence rate was the highest in Guadeloupe and Pays de la Loire (28.30±2.74 and 26.13±0.84 per 100 000 population, respectively) and the lowest in French Guiana and Martinique (15.51±3.50 and 17.29±2.12 per 100 000 population, respectively).

Conclusions The average annual national hospital incidence rate of RRD increased from 2010 to 2015. The hospital incidence rate of RRD seemed to vary according to season and geographical location.

  • epidemiology
  • retina
  • treatment surgery

Data availability statement

Data may be obtained from a third party and are not publicly available. Pseudoanonymised and encrypted data were extracted from the health data hub. Data were handled by authorised personnel in Dijon University Hospital according to health data hub security guidelines.

https://doi.org/10.1136/bjophthalmol-2020-318457

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data may be obtained from a third party and are not publicly available. Pseudoanonymised and encrypted data were extracted from the health data hub. Data were handled by authorised personnel in Dijon University Hospital according to health data hub security guidelines.

    View Full Text

    Footnotes

    • Contributors Conception and design: IBG, ASM, EB, P-HG, AMB, CQ, CPC-G. Data acquisition: IBG, ASM, EB, FB, CQ. Drafting the article: IBG, AMB, CPC-G. Final approval of the version to be published: IBG, ASM, EB, P-HG, FB, AMB, CQ, CPC-G.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Map disclaimer The depiction of boundaries on this map does not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. This map is provided without any warranty of any kind, either express or implied.

    • Competing interests AMB is a consultant for Aerie, Allergan, Bausch Lomb, Santen and Théa. CPC-G is a consultant for Alcon, Allergan, Bausch Lomb, Bayer, Horus, Novartis, Roche and Théa.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles

    • At a glance
      Highlights from this issue
      Frank Larkin
      British Journal of Ophthalmology 2022; 106 i-ii Published Online First: 21 Jul 2022. doi: 10.1136/bjo-2022-322127